West Pharmaceutical Services said net sales for Q3 2024 declined 0.1% to $746.9 million, with organic net sales down 0.5%. Reported-diluted EPS was $1.85, compared with $2.14 in the same period last year.

1. 01

   West Pharmaceutical Services said net sales for Q3 2024 declined 0.1% to $746.9 million, with organic net sales down 0.5%. Reported-diluted EPS was $1.85, compared with $2.14 in the same period last year.

2. 02

   The company said its gross profit margin for Q3 2024 was 35.4%, compared with 38.6% a year earlier, and operating profit was $161.3 million, compared with $177.3 million a year earlier.

3. 03

   The company said it raised its full-year 2024 net sales outlook to $2.875 billion to $2.905 billion from $2.870 billion to $2.900 billion, and its adjusted-diluted EPS outlook to $6.55 to $6.75 from $6.35 to $6.65.

4. 04

   The company said operating cash flow for the first 9 months of 2024 was $463.3 million, down 13.8%, and free cash flow was $191.2 million, down 32.7%. It also said it repurchased 1,409,786 shares for $506.5 million over the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.